Data from Pharmawand - Curated by EPG Health - Date added 19 May 2017

GlaxoSmithKline has announced publication in the New England Journal of Medicine, of a randomised, double-blind, placebo controlled study investigating the efficacy and safety of Nucala (mepolizumab) vs placebo as an add-on therapy in patients with relapsing and/or refractory Eosinophilic Granulomatosis with Polyangiitis (EGPA). In the 52-week pivotal phase III study, mepolizumab treatment demonstrated efficacy based on both co-primary efficacy endpoints and all secondary endpoints. Treatment with mepolizumab was in addition to standard of care (glucocorticoids with or without immunosuppressants). Patients treated with mepolizumab had a significantly greater accrued time in remission (defined as a prednisolone/prednisone dose of below 4mg/day and a Birmingham Vascular Activity Score = 0) over the 52-week treatment period compared to placebo, with 28% of patients on mepolizumab achieving remission for at least 24 weeks versus 3% on placebo (p<0.001).

In addition, a higher proportion of patients in the mepolizumab group were in remission at both Weeks 36 and 48 compared to the placebo group (32% versus 3%; p<0.001). More patients treated with mepolizumab achieved remission within the first 24 weeks of the study and remained in remission until Week 52 compared to those receiving placebo (19% versus 1%; p=0.007). There was no difference between the two treatment groups in the proportion of patients experiencing on-treatment adverse events (97% versus 94%) and overall the adverse event profile for mepolizumab was similar to that seen in previous studies with no new safety signals observed.

See: "Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis." Michael E. Wechsler et al. N Engl J Med 2017; 376:1921-1932 May 18, 2017 DOI: 10.1056/NEJMoa1702079


You will need to login, to leave a comment. is not monitored for collection of adverse event reports. Any adverse events should be reported to your national reporting agency and/or the manufacturer.

Learning Zones

An Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.



See information on psoriasis pathophysiology, signs and symptoms, comorbidities, treatment options, and more.

+ 2 more

IL-17A in Psoriasis

IL-17A in Psoriasis

Experts discuss new targeted therapies for psoriasis at the European Association of Dermatology and Venereology (EADV) Congress.

+ 1 more

Chronic Spontaneous Urticaria (CSU)

Chronic Spontaneous Urticaria (CSU)

Use our patient case studies to discover how experts diagnose and treat chronic spontaneous urticaria.

+ 7 more

Load more

Related Content